Posted on 4 April 2017
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry with an annual turnover of approximately GBP 480 million. Based in Stockholm, Sweden, it operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the UK.
Alistair was presented the award for his research into the impact of chemical contaminants on the health of ecosystems and humans. His work has led to an improved understanding of the current and emerging ecological and health risks posed by chemical contaminants, including pharmaceuticals and nanoparticles, in the natural environment.
Lars Backsell, Chairman of the Board of Recipharm, commented: “We are delighted to present the 2016 award to Professor Boxall. His work, which extends far beyond measuring concentration levels, has helped change attitudes and improve understanding of the detection, fate, effect and risks of contaminants on both human health and whole ecosystems. His research has been integral to building commitment towards environmental matters and is providing valuable guidance for future actions to decrease or avoid the negative effects of chemical contamination.”
Commenting on winning the award, Alistair said: “I am delighted to receive the award. Our research on chemical contaminants has been a real team effort and the progress we have made wouldn’t have been possible without the hard work and commitment of my peers, students and postdocs. It is also a great testament to today’s research programmes that the pharmaceutical industry is recognising the importance of environmental impact and actively adapting practices to reduce the effects of contaminants and safeguard the environment.”